Biotechnology

Enzolytics Announces the Signing of the Business Combination Agreement with Sagaliam Acquisition Corp (SAGA)

September 18, 2023 8:00 AM

COLLEGE STATION, TX / ACCESSWIRE / September 18, 2023 / Enzolytics, Inc. (OTC PINK:ENZC) (https://enzolytics.com). Enzolytics, Inc. announces today that it has executed the binding business combination agreement for the sale of Biogenysis, Inc. ("BGEN") and Virogentics Inc. ("VIRO"), the operating subsidiaries of Enzolytics Inc., to Sagaliam Acquisition Corp (NASDAQ: SAGA) in a transaction valued at $450,000,000. The combined company is expected...

Read more

M2Bio Sciences Pharmacology & Clinical Application of CBD

September 15, 2023 8:30 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 15, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to provide the following update: In recent years, cannabidiol (CBD) has become a subject...

Read more

SciTech Development Announces IRB Approval for Human Clinical Trials

September 14, 2023 10:00 AM

Lead cancer drug candidate, ST-001 nanoFenretinide, has received Institutional Review Board ("IRB") approval for its upcoming clinical trials for T-Cell Lymphomas. GROSSE POINTE FARMS, MI / ACCESSWIRE / September 14, 2023 / SciTech Development ("SciTech" or the "Company"), a clinical-stage pharmaceutical company with a novel and patented drug delivery platform, today announced that the company has received IRB approval for its clinical trial...

Read more

Mindbio Therapeutics CEO Provides Update on Depression Trial & Novel Discoveries in Psychedelics Research

September 14, 2023 9:45 AM

VANCOUVER, BC / ACCESSWIRE / September 14, 2023 / MindBio Therapeutics Corp. (CSE:MBIO)(Frankfurt:WF6), (the "Company" or "MindBio"), Chief Executive Officer Justin Hanka provides corporate update on depression trials and other important developments in the Company in this video address to shareholders. In this video, Justin Hanka, Chief Executive Officer of MindBio, discusses: -Progress in MindBio's Phase 2a Microdosing Clinical Trial using...

Read more

New Cell & Gene Therapy Solutions From Form Bio Analyze Billions of Potential Construct Candidates, Reducing Time-to-Clinic

September 14, 2023 8:47 AM

Powerful New Solutions Help Therapeutic Developers Reduce Time-to-Clinic While Increasing Yield and Safety DALLAS, TX / ACCESSWIRE / September 14, 2023 / Form Bio, the provider of advanced computational life sciences technology, announced today capabilities for cell and gene therapy companies to rapidly model billions of potential construct candidates. With great progress to date but headwinds around safety and manufacturability, Form's new...

Read more

Hemogenyx Pharmaceuticals PLC - Clinical Hold Lift Plan is accepted by FDA

September 14, 2023 2:00 AM

LONDON, UK / ACCESSWIRE / September 14, 2023 / Hemogenyx Pharmaceuticals plc (LSE: HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, announces that the U.S. Food and Drug Administration ("FDA") has accepted the Company's plan to address the FDA's concerns that resulted in a Clinical Hold ("CH") of the HEMO-CAR-T Investigational New Drug ("IND") application. Further to the announcement on 10 July 2023,...

Read more

Biophytis Strengthens its Management Team with the Appointment of its Chief Business Officer

September 14, 2023 1:30 AM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 14, 2023 / Biophytis SA (Nasdaq CM:BPTS, Euronext Growth Paris:ALBPS), (Biophytis), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering from...

Read more

Navigating the Inflation Reduction Act (IRA) with Former FDA Commissioner, Dr. Mark McClellan

September 13, 2023 8:40 PM

Innopiphany specializes in consulting at every level of state and federal policy impact from product-specific evidence strategies and tactical responses to strategic pipeline direction and team education. IRVINE, CA / ACCESSWIRE / September 14, 2023 / Innopiphany LLC., a life science consultancy, will be hosting a webinar on the IRA with former FDA commissioner, Mark McClellan. This 1-hour virtual event will address pressing questions regarding...

Read more

M2Bio-Discovery Centre for AI-Driven Phytomedicine Research: Update

September 13, 2023 8:30 AM

CAPE TOWN, SOUTH AFRICA / ACCESSWIRE / September 13, 2023 / Institute of Biomedical Research Corp. (OTC PINK:MRES), a vanguard entity at the forefront of nutraceutical biotechnology, specializing in alternative plant-based cannabinoids, medical psilocybin, and cutting-edge mental health therapeutic research driven by artificial intelligence (AI), is pleased to present a groundbreaking update on its latest scientific endeavor: M2Bio Sciences...

Read more

FSD Pharma Announces Analyst Coverage Initiated by Singular Research

September 13, 2023 7:30 AM

TORONTO, ON / ACCESSWIRE / September 13, 2023 / FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma" or the "Company"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions for the treatment of challenging neurodegenerative and metabolic disorders, today announced that Singular Research has initiated analyst coverage on FSD Pharma. A copy of the report can be obtained directly from...

Read more

MorphoSys Receives U.S. FDA Fast Track Designation for Tulmimetostat in Endometrial Cancer

September 12, 2023 4:20 PM

Tulmimetostat follows pelabresib (2018) and tafasitamab (2014) as the company's third clinical program to receive Fast Track designation PLANEGG and MUNICH, GERMANY / ACCESSWIRE / September 12, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) today announced that the U.S. Food and Drug Administration (FDA) granted Fast Track designation for tulmimetostat, the company's investigational next-generation dual inhibitor of EZH2 and EZH1, for the treatment...

Read more

CARDIO inCode Study Results Presented at ESC Annual Meeting

September 12, 2023 11:00 AM

Coronary Heart Disease (CHD) prevention nearly twice as effective when using CARDIO inCode as method to target treatment OXFORD, UK / ACCESSWIRE / September 12, 2023 / GENinCode Plc (AIM - GENI), the polygenics company focused on the prevention of cardiovascular disease, announced the presentation by Kaiser Permanente on the 'Utility of the CARDIO inCode-Score CHD polygenic risk score for incident coronary heart disease interplay with lifestyle...

Read more

Brainify.AI Joins Johnson & Johnson Innovation JLABS

September 12, 2023 9:00 AM

Brainify.AI, an innovative company leveraging artificial intelligence to revolutionize the treatment of depression, is excited to announce it has joined Johnson & Johnson Innovation JLABS (JLABS) as a resident company. This marks a significant milestone for Brainify.AI and is another indication of the value and promise the company brings to the medical AI field. NEW CITY, NY / ACCESSWIRE / September 12, 2023 / Brainify.AI, an innovative company...

Read more

First Patients Treated with TISSIUM's Atraumatic Hernia Repair System

September 12, 2023 3:00 AM

ALPHA Study of TISSIUM's ECLIPSIUMTM System Is Underway in Belgium PARIS, FRANCE and BOSTON, MA / ACCESSWIRE / September 12, 2023 / TISSIUM, a privately-owned medical technology company developing biomorphic programmable polymers for atraumatic tissue repair, announced today the first clinical use of TISSIUM's Adhesive Hernia Repair System (the "ECLIPSIUM System") in patients undergoing laparoscopic ventral hernia repair as part of the ALPHA...

Read more

Petros Pharmaceuticals Provides Letter to Shareholders

September 11, 2023 9:00 AM

NEW YORK, NY / ACCESSWIRE / September 11, 2023 / Petros Pharmaceuticals, Inc. (NASDAQ:PTPI), a company focused on expanding consumer access to medication through over the counter (OTC) pathway provides the below Letter to Shareholders: To our valued shareholders, As we approach the fourth quarter of 2023, Petros has been quietly undergoing a change in approach to our business. As we have previously announced, our evolving focus has shifted from...

Read more

Biophytis Obtains FDA Authorization to Initiate the SARA-31 Phase 3 Study in Sarcopenia

September 11, 2023 1:20 AM

PARIS, FRANCE and CAMBRIDGE, MA / ACCESSWIRE / September 11,2023 / Biophytis SA (Nasdaq CM:BPTS)(Euronext Growth Paris:ALBPS), («Biophytis»), a clinical-stage biotechnology company specialized in the development of therapeutics that are aimed at slowing the degenerative processes associated with aging and improving functional outcomes for patients suffering from age-related diseases, including severe respiratory failure in patients suffering...

Read more

Title21 Enables Single-Source Management of Employee Data Leveraging SCIM Integration Standards to Improve Patient Safety and Operational Efficiency

September 8, 2023 2:00 PM

PHOENIX, AZ / ACCESSWIRE / September 8, 2023 / Title21 Health Solutions ("Title21"), the leading innovator of cloud enterprise quality management solutions (EQMS), blood and marrow transplant (BMT) and cell and gene therapy (CGT) data management solutions, today announces the successful development of technology to unify key Identity Access Management (IAM) data with Title21's technology platform via SCIM standard. Developed in collaboration...

Read more

BioInvent initiates subcutaneous arm of Phase 1/2 trial with BI-1206 in solid tumors

September 8, 2023 3:31 AM

LUND, SE / ACCESSWIRE / September 08, 2023 / BioInvent International (STO:BINV) First patient has been enrolled for treatment with subcutaneous BI-1206 in solid tumors Subcutaneous formulation will significantly improve convenience of dosing regimen BioInvent International AB ("BioInvent") (Nasdaq Stockholm: BINV), a biotech company focused on the discovery and development of novel and first-in-class immune-modulatory antibodies for cancer...

Read more

Introducing the ONI Training Kit (TM) dSTORM

September 7, 2023 8:00 AM

A leap into simplifying Super-Resolution Microscopy SAN DIEGO, CA / ACCESSWIRE / September 7, 2023 / ONI, a pioneer in super-resolution imaging solutions, is thrilled to unveil its latest innovation, the ONI dSTORM Training Kit. This new product is designed to provide a simple workflow for new and existing users to master dSTORM super-resolution microscopy. ONI Training Kit™ dSTORM The ONI dSTORM Training Kit takes users through the incredible...

Read more

BioGX Expands Xfree Respiratory PCR With COVID-19/Flu A/Flu B Multiplex, Group A Streptococcus, Mycoplasma Pneumoniae

September 7, 2023 8:00 AM

BIRMINGHAM, AL / ACCESSWIRE / September 7, 2023 / BioGX, a global provider of molecular diagnostic solutions, announces the availability of three new Xfree™ Direct-Sample-to-Answer PCR multiplexes for the detection of Group A Streptococcus, Mycoplasma pneumoniae and Flu A, Flu B, COVID-19 N1/RdRp. Xfree Flu A, Flu B, COVID-19 and Group A Streptococcus were previously CE-IVD marked while Mycoplasma pneumoniae is available as research use only....

Read more